Compare JELD & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JELD | VNDA |
|---|---|---|
| Founded | 1960 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Forest Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 243.5M | 289.0M |
| IPO Year | 2017 | 2006 |
| Metric | JELD | VNDA |
|---|---|---|
| Price | $2.76 | $6.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $4.23 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 1.6M | 1.3M |
| Earning Date | 11-03-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,304,951,000.00 | $212,074,000.00 |
| Revenue This Year | N/A | $12.01 |
| Revenue Next Year | N/A | $21.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 11.12 |
| 52 Week Low | $1.70 | $3.81 |
| 52 Week High | $10.09 | $7.05 |
| Indicator | JELD | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 47.83 | 66.88 |
| Support Level | $2.66 | $6.15 |
| Resistance Level | $3.00 | $7.05 |
| Average True Range (ATR) | 0.15 | 0.45 |
| MACD | 0.08 | 0.09 |
| Stochastic Oscillator | 48.99 | 86.57 |
JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential single and multi-family homes and non-residential buildings. The firm's operating segments are North America, Europe, and Australasia. It generates a majority of its revenue from North America.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.